SCHEMBL5377407

SCHEMBL5377407

Cc1ccc(Cl)c(Oc2ccccc2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 5/20 0.45
MAPT P10636 5/20 0.45
HPGD P15428 3/20 0.45
RAB9A P51151 3/20 0.45
NPC1 O15118 2/20 0.45
CYP2C9 P11712 3/20 0.45
CYP2C19 P33261 3/20 0.45
ALDH1A1 P00352 2/20 0.45
MAPK1 P28482 2/20 0.45
MEN1 O00255 1/20 0.45
USP2 O75604 1/20 0.45
POLB P06746 1/20 0.45
ALOX12 P18054 1/20 0.45
KMT2A Q03164 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
CYP1A2 P05177 2/20 0.44
CYP3A4 P08684 2/20 0.44
HTR2A P28223 2/20 0.44
SLC6A4 P31645 2/20 0.44
KCNH2 Q12809 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9923550 0.89 L3MBTL1 (0.49) L3MBTL1MAPTHPGDRAB9ANPC1
SCHEMBL11428548 0.88 HTR2A (0.50) L3MBTL1MAPTHPGDRAB9ANPC1
SCHEMBL10937945 0.83 CYP1A2 (0.53) L3MBTL1CYP2C9CYP2C19ALDH1A1ALOX12
SCHEMBL13799708 0.82 TTR (0.47) L3MBTL1CYP2C9CYP2C19ALDH1A1MAPK1
SCHEMBL5371133 0.81 SLC6A4 (0.45) L3MBTL1MAPTHPGDRAB9ANPC1
SCHEMBL554766 0.81 TEAD4 (0.57) L3MBTL1MAPTHPGDCYP2C9CYP2C19
SCHEMBL18708752 0.81 ACHE (0.46) L3MBTL1MAPTHPGDRAB9ACYP2C9
SCHEMBL13581464 0.81 MAOB (0.46) L3MBTL1MAPTHPGDRAB9ANPC1
SCHEMBL10544322 0.81 L3MBTL1 (0.44) L3MBTL1MAPTHPGDRAB9ANPC1
SCHEMBL3793518 0.80 LTA4H (0.50) MAPTCYP2C9CYP2C19ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0008735-A1 Process for the preparation of diphenyl ether carboxylic acids BAYER AG (DE) 1980-03-19 EP claimed
EP-1608633-B1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS I FOR TREATING HIV MEDIATED DISEASES HOFFMANN LA ROCHE (CH) 2016-04-20 EP disclosed
EP-1608633-B1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS I FOR TREATING HIV MEDIATED DISEASES HOFFMANN LA ROCHE (CH) 2016-04-20 EP disclosed
CN-100588650-C Non-nucleoside reverse transcriptase inhibitors I for the treatment of HIV mediated diseases HOFFMANN LA ROCHE 2010-02-10 CN disclosed
CN-100469769-C Benzyl-pyridazinons as reverse transcriptase inhibitors ROCHE PALO ALTO LLC (CH) 2009-03-18 CN disclosed
US-7348345-B2 Nonnucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC (US) 2008-03-25 US disclosed
US-7348345-B2 Nonnucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC (US) 2008-03-25 US disclosed
US-20070179157-A1 Nonnucleoside reverse transcriptase inhibitors DUNN JAMES P 2007-08-02 US disclosed
US-20070179157-A1 Nonnucleoside reverse transcriptase inhibitors DUNN JAMES P 2007-08-02 US disclosed
US-7208509-B2 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC (US) 2007-04-24 US disclosed
US-20040198736-A1 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC 2004-10-07 US disclosed
WO-2004085411-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS I FOR TREATING HIV MEDIATED DISEASES F. HOFFMANN-LA ROCHE AG (CH) 2004-10-07 WO disclosed
US-20040192704-A1 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC 2004-09-30 US disclosed
EP-0045423-B1 PROCESS FOR THE ALPHA-HALOGENATION OF POSSIBLY SUBSTITUTED METHYL AROMATICS BAYER AG (DE) 1984-02-22 EP disclosed
EP-0030333-B1 ALKYLDIPHENYL-ETHER SULFONIC ACID HYDRAZIDES, THEIR PRODUCTION AND USE AS BLOWING AGENTS BAYER AG (DE) 1983-03-09 EP disclosed
US-4329499-A Alkyldiphenyl ether-sulphonic acid hydrazides, their preparation and their use as blowing agents BAYER AKTIENGESELLSCHAFT (DE) 1982-05-11 US disclosed
EP-0045423-A1 Process for the alpha-halogenation of possibly substituted methyl aromatics BAYER AG (DE) 1982-02-10 EP disclosed
EP-0030333-A1 Alkyldiphenyl-ether sulfonic acid hydrazides, their production and use as blowing agents BAYER AG (DE) 1981-06-17 EP disclosed
US-4209584-A COATING BY TANDEM GRAVURE, DIFFUSION OF HARDENING AGENT INTO HYDROPHILIC COLLOIDS EASTMAN KODAK COMPANY (US) 1980-06-24 US disclosed
EP-0008735-A1 Process for the preparation of diphenyl ether carboxylic acids BAYER AG (DE) 1980-03-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192704-A1 Non-nucleoside reverse transcriptase inhibitors POLR1A, POLA1, REV1 L3MBTL1 1644/4885MAPT 1407/4885HPGD 818/4885
US-20040198736-A1 Non-nucleoside reverse transcriptase inhibitors POLR1A, POLR2A, POLR2E L3MBTL1 2049/4885MAPT 1798/4885HPGD 983/4885
US-20070179157-A1 Nonnucleoside reverse transcriptase inhibitors RRM2, RRM2B, SAMHD1 L3MBTL1 1581/4885MAPT 2936/4885HPGD 1312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.